JPRN-UMIN000011048已完成2 期
Phase II study of Nab-paclitaxel followed by FEC as neoadjuvant chemotherapy for the operable breast cancer - Phase II study of Nab-paclitaxel followed by FEC as neoadjuvant chemotherapy for the operable breast cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) History of hypersensitivity reaction 2) Active double cancer 3) Other severe complications, such as uncontrolled diabetes mellitus, uncontrolled angina, myocardial infarction within 6 months, heart failure. 4) Severe mental disorder 5) Sever bone marrow suppression, renal dysfunction, liver dysfunction 6) Has watery diarrhea 7) Active infection or potentiality infection 8) History of hypersensitivity for albumin 9) Grade2 or grater peripheral neuropathy 10) Pregnant or lactating women, women who are capable of pregnancy, intend to get pregnant 11) Judged ineligible based on physicians' decision
研究者
相似试验
已完成
2 期
A phase 2 study of nab-Paclitaxel followed by FEC (Fluorouracil, Epirubicin, Cyclophosphamide) as primary therapy for operable breast cancerBreast CancerJPRN-UMIN000009733Hiroshima city hospital40
招募中
2 期
Phase II study of FEC followed by Nab-paclitaxel as Neoadjuvant Chemotherapy for Primary Breast Cancerbreast cancerJPRN-UMIN000006428Toho University Omori Medical Center40
招募中
2 期
Phase II study of FEC followed by Nab-paclitaxel as Neoadjuvant Chemotherapy for Primary Breast CancerBreast cancerJPRN-UMIN000009152Toho University Omori Medical Center40
已完成
2 期
PhaseII study of Nab-paclitaxel followed by EC as neoadjuvant chemotherapy for the operable breast cancerBreast cancerJPRN-UMIN000022931Rakuwakai Otowa Hospital Breast oncology department24
招募中
2 期
A Phase II trial of nab-paclitaxel followed by EC as neoadjuvant chemotherapy for resectable breast cancer.breast cancerJPRN-UMIN000017382Tokyo Women's Medical University,Department of endocrine surgery36